P-糖蛋白谷胱甘肽S-转移酶-π和拓扑异构酶Ⅱα在胃肠肿瘤组织中的表达及意义

Expression of P-gp,GST-π and TopoⅡα in gastric and colorectal cancers and their clinical significance

目的探讨P-糖蛋白(P-gp)、谷胱甘肽S-转移酶-π(GST-π)和拓扑异构酶Ⅱα(TopoⅡα)在胃肠肿瘤组织中的表达以及临床意义。方法采用免疫组化S-P法检测P-gp、GST-π和TopoⅡα在83例胃肠肿瘤组织中的表达情况。结果P-gp、GST-π和TopoⅡα在正常胃肠黏膜组织和胃肠肿瘤组织中的阳性表达率分别为69.9%、65.1%、50.6%和83.1%、85.5%、45.8%,P-gp和GST-π在胃肠肿瘤组织中的表达显著高于正常胃肠黏膜组织(P<0.05);TopoⅡα的表达与肿瘤分化程度有关,分化较低者的阳性率(56.2%)高于分化较高者(31.4%,P<0.05)。结论P-gp、GST-π和TopoⅡα在肿瘤多药耐药性中起重要作用,其介导的耐药机制各不相同,临床检测P-gp、GST-π和TopoⅡα对胃肠肿瘤化疗方案的制定有重要的指导意义。

Objective To study the expression and clinical significance of P-gp,GST-π and Topo Ⅱα in gastric and colorectal cancers. Methods The expression of P-gp, GST-π and Topo Ⅱα in 83 cases with gastric or colorectal cancer were examined by immunohistochemistry S-P. Results The positive expression rates of P-gp, GST-π, Topo Ⅱα in normal tissue and gastric and colorectal cancers were 69.9% , 65.1% , 50.6% and 83.1% , 85.5%, 45.8% , respectively. The positive rates of P-gp and GST-Ⅱα in gastric and colorectal cancer were significantly higher than those in normal gastric and colorectal tissue （ P 〈 0.05 ）. The expression of Topo Ⅱα in poorly differentiated cancers was significantly higher than that in well- and moderately differentiated cancers. There was no correlation between other items and clinicapathological parameters （ P 〉 0. 05 ）. Conclusion P-gp, GST-π and Topo Ⅱα play important role in muhidrug resistance. Their mechanisms of drug resistance were different. The detection of expression of P-gp, GST-π and Topo Ⅱα has an important guiding significance in chemotherapy for gastric and colorectal cancers.